Principais vídeos

Casa
Artigos

Principais vídeos

Tempo todo

Hoje

Essa semana

Este mês

Este ano

Head and Neck Cancer Exercises for Tongue and Swallowing administrator 15 Visualizações • 2 anos atrás

Head and Neck cancer surgery can cause weakness in the tongue, mouth, and can cause issues with swallowing. Radiation for head and neck cancer can cause fibrosis, which leads to tightness, dry mouth, and also causes issues swallowing. In this video, I share exercises to improve motion and strength after head and neck cancer treatment for the tongue and mouth.
This is part 2 of a series. In part 1, I shared head and neck cancer exercises for the jaw, neck, and shoulder that you can find here: https://youtu.be/CEAIRyZ3SfA

00:00 Side effects of head and neck cancer treatment
01:07 Swallowing, Tongue, and Mouth weakness
02:00 Tongue Exercises
03:29 Mouth/Lip Exercise
04:02 Swallowing Exercises
05:17 Summary
-------------------------------------------------------------------------------------------------------

Finding my channel and content helpful and want to support my channel? Your donations are greatly appreciated and can be made here: http://buymeacoffee.com/cancerrehabpt

Join us on Instagram: @cancerrehabpt
https://www.instagram.com/cancerrehabpt/

Check out my website for more information:
http://cancerrehabpt.com

-------------------------------------------------------------------------------------------------------

Use code KELLY10 for 10% off the BEST, medical-quality lymphedema products at BrightLife Direct (*Shipping is free in the US*): https://bit.ly/3udwb1t

For my favorite, go-to products related to management and wellness for lymphatic health and oncology, checkout my storefront!: http://amazon.com/shop/cancerrehabpt

Disclosure: Links included in this description may be affiliate links. If you purchase a product or service with the links that I provide I may receive a small commission. There is no additional charge to you. Thank you for your support! As an Amazon Associate, I earn from qualifying purchases

-------------------------------------------------------------------------------------------------------

*I am a physical therapist, but not your physical therapist. Although I do monitor comments, I cannot respond to personal medical questions. Please know that these are questions for your own doctor or provider as this is general information only. Thanks!

DISCLAIMER
The content of this website, Instagram, YouTube, lectures, webinars, blogs, digital products, or other platforms does not replace the care of physical therapists or other healthcare professionals. This content is in no way to be construed or substituted as physical therapy or any other type of medical advice but is for general education purposes only. Don’t use this content to self-diagnose or self-treat any health, medical, or physical conditions. You agree to hold harmless indemnify Cancer Rehab PT, LLC and its owner/employees for any and all losses, injuries, or damages resulting from any and all claims that arise from your use or misuse of this content. The company cannot guarantee the outcome of educational content or recommendations on the company’s website, social media, products, blog, or email series, and Cancer Rehab PT, LLC’s, and owner, Kelly Sturm’s comments are expressions of opinion only. Keep in mind that we may receive commissions when you click our links and make purchases. However, this does not impact our reviews and comparisons. We try our best to keep things fair and balanced, in order to help you make the best choice for yourself.

Nivolumab/Ipilimumab Approved In Europe For Frontline Unresectable Malignant Pleural Mesothelioma administrator 17 Visualizações • 2 anos atrás

Nivolumab And Ipilimumab Approved In Europe For Frontline Unresectable Malignant Pleural Mesothelioma
➡️ http://MesotheliomaUSA.net

The European Commission has approved the dual immunotherapy combination of nivolumab and ipilimumab for use in the frontline treatment of adults with unresectable malignant pleural mesothelioma.

The regulatory decision was based on findings from the phase 3 CheckMate-743 trial (NCT02899299), which showed that the doublet resulted in a 26% reduction in the risk of death compared with platinum-based, standard-of-care chemotherapy (HR, 0.74; 96.6% CI, 0.60-0.91; P = .002). The median OS with the immunotherapy regimen was 18.1 months (95% CI, 16.8-21.4) vs 14.1 months (95% CI, 12.4-16.2) with chemotherapy, meeting the primary end point of the trial. The 2-year OS rates in the investigative and combination arms were 41% and 27%, respectively.

This is the first positive phase 3 trial of an immunotherapy in the frontline treatment of malignant pleural mesothelioma, according to Bristol Myers Squibb.

“After many years of limited progress in the treatment of malignant mesothelioma, we saw an important clinical benefit for patients with nivolumab plus ipilimumab in the CheckMate-743 trial,” Paul Baas, MD, PhD, of the Department of Thoracic Oncology at the Netherlands Cancer Institute and the University of Leiden, stated in a press release. “With the EC approval of this dual immunotherapy combination, patients and doctors will now have a new treatment option that has shown significant improvements in survival to manage this resistant disease.”

In the open-label, multicenter phase 3 CheckMate-743 trial, investigators examined nivolumab plus ipilimumab vs chemotherapy, which was either pemetrexed and cisplatin or carboplatin, in 605 patients with previously untreated malignant pleural mesothelioma.

Notably, patients who had interstitial lung disease, active autoimmune disease, any conditions that required systemic immunosuppression, or active brain metastases, were not eligible for enrollment. Participants were stratified based on histology, epithelial vs non-epithelial disease, and gender.

Study participants were randomized to receive either nivolumab at 3 mg/kg biweekly plus ipilimumab at 1 mg/kg every 6 weeks (n = 303), or cisplatin at 75 mg/m2 or carboplatin AUC 5 plus pemetrexed at 500 mg/m2 in 21-day treatment cycles for 6 cycles. Patients continued to receive treatment until progressive disease or intolerable toxicity; if in the doublet immunotherapy arm, they received up until 24 months.

The primary end point of the trial was OS in all randomized patients, while other key end points included progression-free survival (PFS), objective response rate (ORR), and duration of response (DOR) per blinded independent central review and RECIST criteria. Other exploratory end points comprised safety, pharmacokinetics, immunogenicity, and patient-reported outcomes.

Additional data from the trial showed that the median PFS with nivolumab plus ipilimumab was shorter than that observed with chemotherapy, at 6.8 months vs 7.2 months, respectively (HR, 1.00; 95% CI, 0.82-1.21). However, the 1-year PFS rates in the investigative and control arms were 30% and 16%, respectively, while the 2-year PFS rates were 24% and 7%, respectively.

The ORRs between the investigative and control arms were similar, at 40% (95% CI, 34.1%-45.4%) and 43% (95% CI, 37.1%-48.5%), respectively. Moreover, the median DOR achieved with the doublet was 11.0 months (95% CI, 8.1-16.5) vs 6.7 months with chemotherapy (95% CI, 5.3-7.1). Thirty-two percent of the responders who received the immunotherapy combination experienced a response that continued at 2 years vs just 8% who received the chemotherapy. The median time to response was 2.7 months with the doublet and 2.5 months with the chemotherapy.

Additional data presented during the 2020 International Association for the Study of Lung Cancer’s World Conference on Lung Cancer Virtual Presidential Symposium showed that the 1-year OS rate with nivolumab plus ipilimumab was 68% vs 58% with chemotherapy. The 2-year OS rates in the investigative and control arms were 41% and 27%, respectively.

Notably, the survival benefit of the dual immunotherapy regimen was observed across all prespecified subgroups, irrespective of epithelioid disease or PD-L1 expression.

Regarding safety, nivolumab plus ipilimumab was determined to be manageable using established adverse effect management protocols.

Nivolumab And Ipilimumab Approved In Europe For Frontline Unresectable Malignant Pleural Mesothelioma
https://www.youtube.com/watch?v=DA_yr5WbOM8
https://www.youtube.com/channe....l/UCOVJwa1zpdmoeq2db

#nivolumab #opdivo #ipilimumab #yervoy #malignant #pleuralmesothelioma #europeancommission #immunotherapy

🔗 https://www.onclive.com/view/n....ivolumab-ipilimumab-

Boozman Secures Improvements in Veterans’ Access to Lifesaving Cancer Screenings administrator 17 Visualizações • 2 anos atrás

U.S. Senator John Boozman (R-AR), a senior member of the Senate Veterans’ Affairs Committee, highlighted passage of a pair of legislative initiatives he championed to modernize Department of Veterans Affairs (VA) breast cancer screening policies and the delivery of lifesaving care for women veterans. The Senate unanimously advanced the Boozman-led measures in March.

SUBSCRIBE to get the latest updates from Sen. Boozman: https://www.youtube.com/user/BoozmanPressOffice

- Visit his website: https://www.boozman.senate.gov/
- Like Senator John Boozman on Facebook: https://www.facebook.com/JohnBoozman/
- Follow @JohnBoozman on Twitter: https://twitter.com/JohnBoozman
- Follow @JohnBoozman on Instagram: https://www.instagram.com/johnboozman/

John Boozman is Arkansas’s senior U.S. Senator and the dean of the state’s Congressional delegation.

A fifth-generation Arkansan, John was raised in Fort Smith and graduated from Northside High School. He went on to play football for the University of Arkansas Razorbacks while completing his pre-optometry requirements. He graduated from the Southern College of Optometry in 1977 and entered private practice that same year co-founding a family business with his brother that would ultimately become a major provider of eye care to Northwest Arkansas.

Decades of experience as a successful healthcare provider and a small business owner guide John’s approach to governing. He is committed to advocating for economic policies that help Arkansas’s small businesses continue to grow and add jobs to our state’s economy. And since agriculture accounts for nearly one-quarter of Arkansas’s economic activity, John has been a consistent champion for our state’s farmers, ranchers and loggers and was instrumental in the fight for an equitable farm bill.

As the son of an Air Force Master Sergeant, John learned at an early age about the sacrifices of our men and women in uniform, as well as the unique challenges military families face. He brings these values with him to Washington where he is committed to enhancing the quality of life for both our veterans and their families. John has authored provisions to extend successful federal homeless veteran programs, expand treatments for our wounded warriors and modernize educational benefits under the GI Bill.

First elected to the Senate in 2010, John was sworn in for a second term on January 3, 2017. Prior to serving in the Senate, he represented the people of the Third District of Arkansas in the U.S. House of Representatives

John serves on four committees in the 117th Congress:
- Committee on Agriculture, Nutrition, and Forestry (Ranking Member)
- Committee on Appropriations (Ranking Member, Subcommittee on Military Construction, Veterans Affairs and Related Agencies)
- Committee on Environment & Public Works
- Committee on Veterans' Affairs